Stock Price, News, Quote and Profile of XORTX THERAPEUTICS INC(NASDAQ:XRTX) stock

XORTX THERAPEUTICS INC

NASDAQ:XRTX (12/31/2024, 8:00:02 PM)

1.1296

-0.05 (-3.86%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryPharmaceuticals

GICS SubIndustryPharmaceuticals

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%69.69%

Sales Q2Q%N/A

CRS5.61

6 Month-35.82%

Overview

Earnings (Last)11-12 2024-11-12/bmo

Earnings (Next)N/A N/A

Ins Owners3.11%

Inst Owners6.37%

Market Cap3.93M

Shares3.48M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts80

Short Float %0.03%

Short Ratio0.05

IPO09-30 2015-09-30

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

XORTX Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Calgary, Alberta. The company went IPO on 2015-09-30. The firm develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. The company is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The firm has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The firm's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.